

**CHARTER FOR THE  
RESEARCH AND DEVELOPMENT COMMITTEE  
OF THE BOARD OF DIRECTORS  
OF  
CRINETICS PHARMACEUTICALS, INC.**

**I. PURPOSE**

The purpose of the Research and Development Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of Crinetics Pharmaceuticals, Inc. (the “*Company*”) shall be to advise and assist the Board with the oversight of the following matters:

- a) Research and Development strategy;
- b) Pipeline prioritization and investment including business development activities related to product candidates, medicines, modalities, and the acquisition of technologies;
- c) Scientific matters involving the safety and effectiveness of the Company’s drug candidates

**II. MEMBERSHIP**

The Committee shall be composed of not less than three non-employee directors, all of whom shall meet the Nasdaq Stock Market LLC (“*Nasdaq*”) requirements for director independence. The Committee members shall be appointed by the board on the recommendations of the directors and Corporate Nominating and Governance Committee for one-year terms or until their earlier resignation or death. The chair shall be designated by the Board. The chair and Committee members will serve at the discretion of the Board.

**III. CORPORATE STAFF**

The Chief Medical Officer of the Company (“*CMO*”), the Chief Scientific Officer (“*CSO*”) and Chief Development Officer (“*CDO*”) shall support the Committee and shall attend Committee meetings as directed by the Committee chair. The Committee and its members may talk directly and privately with any members of management in discharging Committee responsibilities. The Committee or its chair may request that any officer or employee of the Company attend any Committee meeting. The chair may designate any officer or employee of the Company for attendance at any Committee meeting.

**IV. RESPONSIBILITIES**

In the discharge of its responsibilities the Committee will:

- 1. Review, evaluate, and advise the board and management regarding the long-term strategic goals and objectives and the quality and direction of the Company’s research and development programs.

2. Review and advise management and the Board on the overall strategic direction and investment in the Company's research, development and technology programs;
3. Regularly review research and development programs and progress against goals;
4. Assess the capabilities of key scientific and medical personnel and the depth and breadth of the scientific resources available to the Company;
5. Provide guidance to management and the Board on emerging trends in healthcare, discovery research and development;
6. Recommend approaches to acquiring and maintaining technology (e.g., grants, collaborative efforts, alliances, and venture capital) and advise the Board and management on the scientific aspects of major acquisitions and business development transactions;
7. Review and advise on regulatory strategy including review of efficacy and safety profile of new drug products before they are launched by the Company;
8. The Committee shall also undertake such additional activities within the scope of its primary functions as the Committee may from time to time determine.

## **V. ADMINISTRATIVE MATTERS**

1. *Meetings:* The Committee will meet from time to time as required, coincident with regularly scheduled Board meeting and more frequently as circumstances require. The Committee has the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Company's bylaws that are applicable to the Committee. The Committee shall meet at least four times per year and at such other times as it determines to be necessary or appropriate and shall report at the next board meeting following each such Committee meeting.
2. *Minutes:* The Committee will maintain written minutes of its meetings, which minutes will be filed with the minutes of the meetings of the Board.
3. *Reports:* The Committee shall make regular reports to the Board of actions taken at its regular and/or special meetings.
4. *Compensation:* Members of the Committee shall receive such fees for their service as Committee members as may be determined by the Board in its sole discretion.
5. *Other:* The Committee may, in its discretion, delegate all or a portion of its duties and responsibilities to the chair or a subcommittee. The Committee is authorized to select and retain its own scientific, medical and risk management advisors at the Company's expense. The Committee should review and reassess the adequacy of this charter of the Committee from time to time and recommend any proposed changes to the Board for approval.